SEC-sourced researchBeta
PRLD
Prelude Therapeutics Inc
Company comparison ↗
Data passport
- CIK
- 0001678660
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 10, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 7,000,000.0000 | Mar 10, 2026 |
| December 2025 | 12,140,000.0000 | Mar 10, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 12,140,000.0000 | -99,498,000.0000 | -56,302,000.0000 | 141,315,000.0000 | 72,678,000.0000 | Mar 10, 2026 |
| December 2024 | 7,000,000.0000 | -127,173,000.0000 | -102,888,000.0000 | 175,515,000.0000 | 44,056,000.0000 | Mar 10, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $12.14M | December 2025 | Mar 10, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $7M | December 2024 | Mar 10, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$99.5M | December 2025 | Mar 10, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$56.3M | December 2025 | Mar 10, 2026 | 10-K |
| Total assetsAssets | $141.32M | December 2025 | Mar 10, 2026 | 10-K |
| Total liabilitiesLiabilities | $72.68M | December 2025 | Mar 10, 2026 | 10-K |